Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477968 · ClinicalTrials.gov registry record
ThRombosis ExclUsion STudy
A clinical trial, sponsored by Diagnostica Stago.
- Terminated
- Registry status
- 5,935
- Enrollment target
NCT03477968: Clinical Trial study, sponsored by Diagnostica Stago.
NCT03477968 is a clinical trial that was terminated before completion, run by Diagnostica Stago. The registered enrollment target is 5,935 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477968 was terminated before completion, sponsored by Diagnostica Stago.
- TERMINATED
- Registry status
- 5,935 participants
- Enrollment target
Study Summary
Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity. Secondary objectives: 1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV) 2. To constitute a plasma bank to be used for future studies with other DDi assays under development by Stago.
Primary Outcome
According to the ThRombosis ExclUsion STudy (TRUST) protocol, the primary objective of the study was to demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity. The first step was to evaluate the stability of the plasmabank using VIDAS system. The preliminary results showed that the plasmabank was unusable with a high r
Interventions
- DIAGNOSTIC_TEST DDimer test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,935 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2024-09-05 |
Why NCT03477968 stopped before completion
NCT03477968 is an observational study that tracks outcomes without assigning an intervention. Its 5,935 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which DDimer test is the first listed.
NCT03477968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03477968 about?
NCT03477968 is a clinical study titled "ThRombosis ExclUsion STudy". Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity. Secondary objectives: 1. To estimat...
What is the current status of trial NCT03477968?
This trial is currently terminated. The enrollment target is 5,935 participants. The study started on 2018-06-25. Estimated completion is 2024-09-05.
What interventions are being tested in trial NCT03477968?
The interventions under investigation include: DDimer test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03477968?
This trial is sponsored by Diagnostica Stago, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI